{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:05:10Z","timestamp":1782831910061,"version":"3.54.5"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,9]]},"DOI":"10.7759\/cureus.89689","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T14:14:48Z","timestamp":1754748888000},"source":"Crossref","is-referenced-by-count":2,"title":["Concurrent Thyroiditis and Hypophysitis in a Patient Receiving Dual Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma"],"prefix":"10.7759","author":[{"given":"Hima","family":"Darapu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryn E","family":"Kormanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright JJ","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021, 17:389-99. 10.1038\/s41574-021-00484-3","journal-title":"Nat Rev Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.505","article-title":"Immune checkpoint inhibitors-induced endocrinopathies: assessment, management and monitoring in a comprehensive cancer centre","volume":"7","author":"Elshafie O","year":"2024","unstructured":"Elshafie O, Khalil AB, Salman B, Atabani A, Al-Sayegh H. Immune checkpoint inhibitors-induced endocrinopathies: assessment, management and monitoring in a comprehensive cancer centre. Endocrinol Diabetes Metab. 2024, 7:e00505. 10.1002\/edm2.505","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell EP","year":"2020","unstructured":"Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL. Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls. Curr Oncol Rep. 2020, 22:39. 10.1007\/s11912-020-0897-9","journal-title":"Curr Oncol Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101660","article-title":"Immune checkpoint inhibitor-related thyroid dysfunction","volume":"36","author":"Iwama S","year":"2022","unstructured":"Iwama S, Kobayashi T, Yasuda Y, Arima H. Immune checkpoint inhibitor-related thyroid dysfunction. Best Pract Res Clin Endocrinol Metab. 2022, 36:101660. 10.1016\/j.beem.2022.101660","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot JM","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al.. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016, 54:139-48. 10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luaf093","article-title":"Co-occurrence of hypophysitis and thyroiditis induced by PD-L1 inhibitor avelumab: clinical insights","volume":"3","author":"Zavgorodneva Z","year":"2025","unstructured":"Zavgorodneva Z, Khan M, Guber H. Co-occurrence of hypophysitis and thyroiditis induced by PD-L1 inhibitor avelumab: clinical insights. JCEM Case Rep. 2025, 3:luaf093. 10.1210\/jcemcr\/luaf093","journal-title":"JCEM Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis P","year":"2024","unstructured":"Gougis P, Jochum F, Abbar B, et al.. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective. EClinicalMedicine. 2024, 70:102536. 10.1016\/j.eclinm.2024.102536","journal-title":"EClinicalMedicine"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.582394","article-title":"Case report: ipilimumab-induced panhypophysitis: an infrequent occurrence and literature review","volume":"10","author":"Barnabei A","year":"2020","unstructured":"Barnabei A, Carpano S, Chiefari A, et al.. Case report: ipilimumab-induced panhypophysitis: an infrequent occurrence and literature review. Front Oncol. 2020, 10:582394. 10.3389\/fonc.2020.582394","journal-title":"Front Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.06.008","article-title":"Risk of pituitary immune-related adverse events caused by immune checkpoint inhibitors: a systematic review and meta-analysis","author":"Li Z","year":"2025","unstructured":"Li Z, Liu Z, Wei H, Jin S, Sun Y, Zhang Y, Liu Y. Risk of pituitary immune-related adverse events caused by immune checkpoint inhibitors: a systematic review and meta-analysis. Endocr Pract. 2025, 10.1016\/j.eprac.2025.06.008","journal-title":"Endocr Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.03.094","article-title":"Simultaneous hypophysitis with adrenal crisis and thyroiditis due to immunotherapy: a case report","volume":"30","author":"Aldrete K","year":"2024","unstructured":"Aldrete K, Shahla L. Simultaneous hypophysitis with adrenal crisis and thyroiditis due to immunotherapy: a case report. Endocr Pract. 2024, 30:164. 10.1016\/j.eprac.2024.03.094","journal-title":"Endocr Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7098","article-title":"Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival","volume":"21","author":"Johnson J","year":"2023","unstructured":"Johnson J, Goldner W, Abdallah D, Qiu F, Ganti AK, Kotwal A. Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival. J Natl Compr Canc Netw. 2023, 21:281-7. 10.6004\/jnccn.2022.7098","journal-title":"J Natl Compr Canc Netw"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae200","article-title":"Pembrolizumab-induced thyroiditis, hypophysitis and adrenalitis: a case of triple endocrine dysfunction","volume":"2","author":"Rossi S","year":"2024","unstructured":"Rossi S, Silvetti F, Bordoni M, Ciarloni A, Salvio G, Balercia G. Pembrolizumab-induced thyroiditis, hypophysitis and adrenalitis: a case of triple endocrine dysfunction. JCEM Case Rep. 2024, 2:luae200. 10.1210\/jcemcr\/luae200","journal-title":"JCEM Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030415","article-title":"Pituitary enlargement and hypopituitarism in patients treated with immune checkpoint inhibitors: two sides of the same coin?","volume":"13","author":"Chiloiro S","year":"2023","unstructured":"Chiloiro S, Giampietro A, Bianchi A, et al.. Pituitary enlargement and hypopituitarism in patients treated with immune checkpoint inhibitors: two sides of the same coin?. J Pers Med. 2023, 13:415. 10.3390\/jpm13030415","journal-title":"J Pers Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/398167-concurrent-thyroiditis-and-hypophysitis-in-a-patient-receiving-dual-immune-checkpoint-inhibitor-therapy-for-metastatic-melanoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T14:14:48Z","timestamp":1754748888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/398167-concurrent-thyroiditis-and-hypophysitis-in-a-patient-receiving-dual-immune-checkpoint-inhibitor-therapy-for-metastatic-melanoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.89689","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,9]]}}}